Over the past decade, many payers in the United States have pivoted their organizational philosophy and business model to take on an expanded role in the healthcare ecosystem—evolving from health insurance companies primarily focused on managing risk to healthcare partners responsible for the coordination and provision of high-quality care for members and customers. In our view, this evolution was in part driven by the increased focus on value-based payment (VBP) models as part of the Affordable Care Act: payers and providers sought new ways to work closely together in organizing new models of care to take on risk. This translates into current demand-side pressure on payers to focus on quality (for example, through quality metrics such as HEDIS
scores and Centers for Medicare & Medicaid Services Star ratings), affordability and customer experience as equally important and mutually beneficial objectives. While every payer is different, many have a common need for sound clinical insight, judgement, and leadership across a range of business priorities critical to future success of the organization.
In this context, the role of payer Chief Medical Officers (CMOs) is evolving rapidly to ‘catch up’ with the growing and diversified needs of their organizations. Whereas traditionally the CMO was first and foremost seen as a ‘physician executive’ focused on core functional areas such as medical policy and provider relations, the payer CMO is increasingly viewed as a strategic business partner, responsible for designing, leading, and supporting important clinically oriented initiatives across the organization. Recent public health and regulatory disruptions are further accelerating this trend. COVID-19 has thrust the payer CMO to the forefront of C-suite business decisions across a range of high stakes, time sensitive priorities (for example, employee well-being, COVID-19 public health guidelines, virtual care medical policies, vaccine access strategy). Recent changes
to direct contracting and healthcare data transparency rules, along with any additional future regulatory changes, are likely to increase the need for CMO collaboration on important strategic and operational decisions. Furthermore, a deft CMO will need to proactively address barriers to receiving care in efforts to promote health equity, both physical and mental. Payer CMOs may focus on being attuned to member concerns and frustrations, such as price transparency. Prior work has established that access to information personalized to a member’s situation can empower members to make decisions based on factors important to them, such as cost.
Each topic further highlights the evolving nature of this role.
We see a common set of payer priorities where the CMO can add value as a strategic business partner over the next three-to-five years (Exhibit 1). While the specific strategy and market context of each payer will dictate relative prioritization across these items, all remain important for the CMO to consider on behalf of the organization. Taken collectively, these strategic priorities impact the majority of payer value creation levers (for example, medical cost reduction through VBP and policy, revenue yield from clinical acquisitions, growth/retention from virtual first products) and all have one thing in common: clinical leadership is a differentiating factor for success. As such, payers who are quick to embrace the expanded priorities of the CMO as a strategic thought partner will achieve tangible bottom-line impact in the near term and build competitive differentiation in the long term.
While the strategic areas of focus where the CMO can add value should be clear to C-suite executives, determining how the CMO can add value is equally important. This is particularly true if an organization is accustomed to the CMO playing a more traditional, narrowly defined role; in this context, the ability of the CMO (and his or her team) to build connections with the business and identify ways to add value in the current operating model is paramount. In order to be an effective CMO, we see five common ‘CMO roles,’ which will be required (not mutually exclusive), in addition to a set of critical underlying capabilities (Exhibit 2).
The most effective and strategic CMOs will be comfortable playing each of these various roles (leveraging their extended team where needed) and adept at recognizing which role will be most impactful to achieve the business objectives at hand. To that end, when assessing each payer’s strategic priority, it is clear that specific CMO roles can add more value than others (Exhibit 3). If, for example, a payer is most interested in partnering with new, innovative players to reshape member care journeys in their market, then a CMO playing a care model innovator role will add the most value. However, if a payer is focused on expanding VBP and population health programs that require strong local physician partnership and engagement to succeed, then a provider liaison role is critical. It is worth pausing to consider which dominant CMO role(s) exist(s) within an organization and how these roles align with current strategic priorities. Over the long term, a mismatch between the role the CMO is playing and the strategic priorities of the organization will underleverage the clinical expertise in the organization and erode value.
Moving forward, several ‘no regrets’ actions can support and enable the CMO as a strategic business partner and leverage his or her expertise to maximize value across the organization. These include:
- Launch a cross-functional team of business leaders to assess and update current strategic priorities based on the organization’s broader clinical goals and objectives (as defined by CMO and supporting team). This initiative could be part of the annual strategic planning process.
- Align on a set of clinical metrics with direct linkage to enterprise value creation and member health, in order to create a clear mandate and accountability for the CMO that prioritizes high-value areas.
- For each enterprise strategic priority where the CMO is involved, be explicit on the role expectations for the CMO (and the team) to add value in this specific context.
- Proactively create a structured and robust operating model (for example, cadence of interaction, decision rights on clinical topics, cross-functional team composition) between the CMO and other parts of the business to allow each component to ‘run the business’ activities swiftly and with clinical intelligence that ensures the whole is greater than the sum of its parts.
- Build a team around the CMO that combines deep clinical expertise with clinical ‘translators’ who can work closely with business partners to infuse that expertise in a value-added way, similar to advanced analytics systems.
- Create a culture of embracing innovation, allowing the CMO to usher in new models of member engagement that directly impact member wellness (for example, omnichannel methods of member outreach such as mobile apps or text, earlier member intervention such as preventive education about chronic conditions).
The role of the payer CMO has never been more important. This executive is uniquely positioned to positively influence decisions and outcomes for a broad and diverse group of healthcare stakeholders, including members, customers, and providers. Organizations and CMOs that recognize this value at stake and embrace the evolution of this role stand to benefit greatly, as do their beneficiaries.